In this review, we therefore summarise the existing literature on putative roles of IgE class antibodies in natural immunosurveillance that may influence cancer risk; and we consider how this may translate to increased efficacy for IgE as a novel anti-cancer therapeutic modality. The gene discussed is IGHE; the disease is cancer.